Third, the same mechanism-based therapy could be used for CDD patients of all ages since loss of CDKL5 does not exacerbate age-associated sleep deteriorations, implying that the mechanisms underlying the sleep disturbances in CDD may not alter with age. Here, CDKL5 is linked to craniodiaphyseal dysplasia.